Trials / Recruiting
RecruitingNCT07332455
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK5471713 | GSK5471713 will be administered at different dose levels based on the dose escalation study design |
Timeline
- Start date
- 2026-02-10
- Primary completion
- 2028-03-24
- Completion
- 2030-03-26
- First posted
- 2026-01-12
- Last updated
- 2026-02-19
Locations
3 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07332455. Inclusion in this directory is not an endorsement.